|
|
|
Clinical Research Detail |
|
|
|
Title Of Study |
EGF102988 : This is a randomised, double-blind, placebo-controlled, multicentre, global Phase III trial comparing the efficacy of adjuvant oral lapatinib versus placebo in high-risk subjects with head and neck cancer following surgery. Lapatinib or placebo will be administered post-operatively in combination with chemoradiotherapy followed by maintenance with lapatinib or placebo for 1 year. The primary goal is to determine if lapatinib is effective at reducing the recurrence of the disease in these high-risk patients.
|
|
|
Disease Condition |
Squamous Cell Carcinoma of the Head & Neck
|
|
|
Phase of Trial |
Phase-3
|
Discipline |
Oncology
|
|
|
Start date of Trial |
2/12/2007
|
Closing Date of Trial |
2/12/2007
|
|
|
|